Novavax Investor Relations

Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study

04/18/2026

Sanofi presented positive results from COMPARE, the first head-to-head, double-blind, randomized Phase 4 study powered to directly compare the tolerability profiles of Novavax’s protein-based non-mRNA COVID-19 vaccine Nuvaxovid™ and mNEXSPIKE, Moderna's latest mRNA COVID-19 vaccine. The study showed that Nuvaxovid demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE across all pre-specified endpoints.

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

11/04/2025

Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy,...

Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment

10/07/2025

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi to take full...

Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP 

09/19/2025

Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices (ACIP) Meeting

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

09/04/2025

Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL...